Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Membrane protein integrated technologies development for drug design

Project description

Innovative membrane protein structural and biochemical analysis for drug discovery

Cellular proteins represent the majority of drug targets and are used as pharmaceuticals in biotechnology. Most commercial drugs are the results of conventional drug discovery. However, the information obtained from three-dimensional protein structures enables rational drug design with improved selectivity and pharmaceutical properties. Funded by the Marie Skłodowska-Curie Actions programme, the ProMeTeus consortium of international academia and industrial partners aims to develop a high-quality multidisciplinary training and research platform centering on proteins as molecular tools for drug discovery and delivery. The project will focus on membrane protein structural biology and biochemistry as well as state-of-the-art facilities to study high-throughput target selection and expression.

Objective

The aim of the ProMeTeus Consortium is to provide high-quality multidisciplinary knowledge through training and research on the development of protein studies as molecular tools for drug development and drug delivery. The focus of the action is the creation of a synergistic pipeline to yield target membrane protein structures and characterization and bioactive molecules design, harnessing the complementary skills from Academic and SME participants. We propose to join key expertise in protein structural biology and biochemistry with state-of-the art facilities for membrane protein high-throughput target selection and expression. A strategic contribution will be provided by SME in key technologies (virtual screening, detergent science, organic synthesis and biotech) and in exploitation, dissemination and resource acquisition skills. We will deliver crucial data for the development of new leads for health issues such as the design of new antibiotics or new strategies for theranostics and foster a synergistic approach to novel bioactive compounds development between academic and SME. The acquisition of new skill from staff will come from secondments aimed at training on research topics not available at the home institutions and attendance to courses, workshops, seminar and conferences. In an era where academic institutions are called to participate actively in technological and industrial development and SME provide services to and benefit of the wide breadth of academic research programs, we will foster a culture of synergistic exchange and cross-fertilization.
The consortium consists of 9 beneficiaries and 2 partners , of which 7 are academic and 4 are SME. During 4 years 16 ESRs, 6 ERs and 2 research managers will be seconded to 1 Institutions, where they will be supported by a team of leading scientists. The Network will promote the integration of academic and SME in combining excellent science with entrepreneurial approach and high-throughput methodologies.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-RISE-2018

See all projects funded under this call

Coordinator

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA
Net EU contribution
€ 128 800,00
Address
Piazzale Aldo Moro 5
00185 Roma
Italy
Region
Centro (IT) Lazio Roma
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 128 800,00

Participants (8)

Partners (2)